Patents Assigned to HDL Therapeutics, Inc.
  • Patent number: 11903965
    Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: February 20, 2024
    Assignee: HDL Therapeutics, Inc.
    Inventors: Hollis Bryan Brewer, Jr., Michael M. Matin
  • Patent number: 11400188
    Abstract: The present specification discloses plasma processing systems that include a number of different fluid flow circuits that are defined by sources of fluid, fluid lines, fluid flow paths, waste containers, a mixer, a separator, valves, and a pump. The systems also include a connector tube and a solvent extraction device, wherein the connector tube and solvent extraction device are configured to be alternatively inserted in a same position along a fluid flow line. In addition, the systems include a controller that is configured to execute a plurality of programmatic instructions to open and close each of a first fluid flow line valve, a second fluid flow line valve, a third fluid flow line valve, and a fourth fluid flow line valve in a predetermined sequence to either enable or prevent a flow of fluid through various fluid flow lines.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 2, 2022
    Assignee: HDL Therapeutics, Inc.
    Inventors: Hollis Bryan Brewer, Jr., Michael M. Matin, Timothy Jon Perlman
  • Patent number: 11033582
    Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: June 15, 2021
    Assignee: HDL Therapeutics, Inc.
    Inventors: Hollis Bryan Brewer, Jr., Michael M. Matin
  • Patent number: 10821133
    Abstract: Systems and methods for acquiring, preserving, and administering delipidated plasma. Extracted delipidated plasma, comprising pre-beta HDL, is obtained and are spot tested to establish baseline amounts or concentrations of pre-beta HDL. The batches are subjected to preservation, stored, and then prepared again for use at some later date. A portion of the batch may be tested again to determine if the pre-beta HDL in the delipidated plasma has degraded or is no longer effective.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 3, 2020
    Assignee: HDL Therapeutics, Inc.
    Inventors: Hollis Bryan Brewer, Jr., Michael M. Matin